Sanofi position in IMRX
Immuneering Corp · Health Care
Sanofi reported holding 2,708,559 shares of IMRX (Immuneering Corp) in its Q3 2026 13F filing — a position valued at US$11.1M, representing 1.76% of its reported portfolio and ranking #12 among its reported holdings. Sanofi has disclosed IMRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-05 · Source: SEC EDGAR Form 13F-HR
How Sanofi's IMRX position evolved
Sanofi first disclosed a stake in IMRX in Q3 2025 at 2,708,559 shares (US$19.0M). Across 5 filings, Sanofi held the position steady without any share-count change. The most recent filing (Q3 2026) shows 2,708,559 shares valued at US$11.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.71M | $18.96M | New |
| Q4 2025 | 2.71M | $17.82M | Hold |
| Q1 2026 | 2.71M | $14.27M | Hold |
| Q2 2026 | 2.71M | $13.52M | Hold |
| Q3 2026 | 2.71M | $11.09M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IMRX and 13F data
IMRX (Immuneering Corp) is a Health Care company. 59 other funds we track also report a position in IMRX — the largest reported positions include DCF Advisers, LLC (US$3.9M), ALETHEA CAPITAL MANAGEMENT, LLC (US$2.4M), Occam Crest Management LP (US$1.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IMRX
- DCF Advisers, LLC 790.00K sh · $3.94M · Q2 2026
- ALETHEA CAPITAL MANAGEMENT, LLC 472.94K sh · $2.36M · Q2 2026
- Occam Crest Management LP 278.50K sh · $1.13M · Q2 2026
- BRANDYWINE MANAGERS, LLC 55.07K sh · $274.78K · Q2 2026
- Flower City Capital 60.03K sh · $245.82K · Q3 2026
FAQ
How long has Sanofi held IMRX?
Sanofi has disclosed IMRX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is Sanofi's current position in IMRX?
As of Q3 2026, Sanofi holds 2.71M shares of IMRX (Immuneering Corp), valued at $11.09M, representing 1.76% of its reported portfolio and ranking #12.
Has Sanofi been buying or selling IMRX?
In the latest 13F filing (Q3 2026), Sanofi held unchanged its position in IMRX.
Which other funds hold IMRX?
Other major institutional holders of IMRX include DCF Advisers, LLC, ALETHEA CAPITAL MANAGEMENT, LLC, Occam Crest Management LP, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.